RT Journal Article
SR Electronic
T1 COVID-19 Projections for K12 Schools in Fall 2021: Significant Transmission without Interventions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.10.21261726
DO 10.1101/2021.08.10.21261726
A1 Zhang, Yiwei
A1 Johnson, Karl
A1 Yu, Zhuoting
A1 Fujimoto, Akane B.
A1 Lich, Kristen Hassmiller
A1 Ivy, Julie
A1 Keskinocak, Pinar
A1 Mayorga, Maria
A1 Swann, Julie L.
YR 2021
UL http://medrxiv.org/content/early/2021/09/03/2021.08.10.21261726.abstract
AB Background Millions of primary school students across the United States are about to return to in-person learning. Amidst circulation of the highly infectious Delta variant, there is danger that without the appropriate safety precautions, substantial amount of school-based spread of COVID-19 may occur.Methods We used an extended Susceptible-Infected-Recovered computational model to estimate the number of new infections during 1 semester among a student population under different assumptions about mask usage, routine testing, and levels of incoming protection. Our analysis considers three levels of incoming protection (30%, 40%, or 50%; denoted as “low”, “mid”, or “high”). Universal mask usage decreases infectivity by 50%, and weekly testing may occur among 50% of the student population; positive tests prompt quarantine until recovery, with compliance contingent on symptom status.Results Without masking and testing, more than 75% of susceptible students become get infected within three months in all settings. With masking, this values decreases to 50% for “low” incoming protection settings (“mid”=35%, “high”=24%). Testing half the masked population (“testing”) further drops infections to 22% (16%, 13%).Conclusion Without interventions in place, the vast majority of susceptible students will become infected through the semester. Universal masking can reduce student infections by 26-78%, and biweekly testing along with masking reduces infections by another 50%. To prevent new infections in the community, limit school absences, and maintain in-person learning, interventions such as masking and testing must be implemented widely, especially among elementary school settings in which children are not yet eligible for the vaccine.Competing Interest StatementDr. Ivy reported receiving grants from the CDC, CSTE, NCATS, and NC State University during the conduct of the study. Dr. Mayorga reported receiving grants from the NCATS/NIH, CSTE, CDC, and NC State University during the conduct of the study. Dr. Keskinocak reported receiving grants from CDC, CSTE, and Georgia Institute of Technology during the conduct of the study. Dr. Swann reported receiving grants from NCATS/NIH, CDC, CSTE, and NC State University during the conduct of the study. No other disclosures were reported.Funding StatementThis research was supported by grant UL1TR002489 from the NCATS/NIH; Cooperative Agreement NU38OT000297 from the CSTE and the CDC; grant KL2TR002490 from the NCATS/NIH; The research also received partial support from the Georgia Institute of Technology and NC State University. The funders had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, and the decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was exempted by the UNC Institutional Review Board (#20-2087).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data utilized for the development of this model is available upon request.